AU2003278811A8 - Ldlrs as modifiers of the p53 pathway and methods of use - Google Patents

Ldlrs as modifiers of the p53 pathway and methods of use

Info

Publication number
AU2003278811A8
AU2003278811A8 AU2003278811A AU2003278811A AU2003278811A8 AU 2003278811 A8 AU2003278811 A8 AU 2003278811A8 AU 2003278811 A AU2003278811 A AU 2003278811A AU 2003278811 A AU2003278811 A AU 2003278811A AU 2003278811 A8 AU2003278811 A8 AU 2003278811A8
Authority
AU
Australia
Prior art keywords
ldlrs
modifiers
pathway
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003278811A
Other versions
AU2003278811A1 (en
Inventor
Carol L O'brien
Mark E Maxwell
Tak Hung
Kim Lickteig
Michael Costa
Mark R Lackner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of AU2003278811A8 publication Critical patent/AU2003278811A8/en
Publication of AU2003278811A1 publication Critical patent/AU2003278811A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis
AU2003278811A 2002-09-16 2003-09-15 LDLRs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE Abandoned AU2003278811A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41098802P 2002-09-16 2002-09-16
US60/410,988 2002-09-16
PCT/US2003/028902 WO2004024881A2 (en) 2002-09-16 2003-09-15 LDLRs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE

Publications (2)

Publication Number Publication Date
AU2003278811A8 true AU2003278811A8 (en) 2004-04-30
AU2003278811A1 AU2003278811A1 (en) 2004-04-30

Family

ID=31994232

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003278811A Abandoned AU2003278811A1 (en) 2002-09-16 2003-09-15 LDLRs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE

Country Status (2)

Country Link
AU (1) AU2003278811A1 (en)
WO (1) WO2004024881A2 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407062B1 (en) * 1995-09-27 2002-06-18 St. Jude Children's Research Hospital ARF-P19, a novel regulator of the mammalian cell cycle
US7259278B2 (en) * 2000-11-29 2007-08-21 Cytoskeleton Inc. Anti-S-phase tubulin ligands

Also Published As

Publication number Publication date
AU2003278811A1 (en) 2004-04-30
WO2004024881A3 (en) 2004-07-01
WO2004024881A2 (en) 2004-03-25

Similar Documents

Publication Publication Date Title
AU2003213606A8 (en) Mp53s as modifiers of the p53 pathway and methods of use
EP1402053A4 (en) CHDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
EP1466175A4 (en) SPHKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
AU2003248879A1 (en) RABS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
AU2003272390A8 (en) Ampds as modifiers of the p21 pathway and methods of use
AU2003295881A8 (en) Lamps as modifiers of the p53 pathway and methods of use
AU2003303094A8 (en) Mat2as as modifiers of the p53 pathway and methods of use
AU2003274911A8 (en) Mrbs as modifiers of the rb pathway and methods of use
AU2003278811A8 (en) Ldlrs as modifiers of the p53 pathway and methods of use
AU2003251826A8 (en) Mp21s as modifiers of the p21 pathway and methods of use
EP1534852A4 (en) CSNK1GS AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
AU2003263993A8 (en) Mp2153s as modifiers of the p21 or p53 pathway and methods of use
EP1633852A4 (en) Sppls as modifiers of the p53 pathway and methods of use
AU2003294499A8 (en) Rhebs as modifiers of the rb pathway and methods of use
EP1578945A3 (en) Cct6s as modifiers of the rb pathway and methods of use
AU2003299990A8 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
AU2003217851A8 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
AU2003248876A1 (en) MP53S AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
AU2002357817A8 (en) Klcs as modifiers of the p53 pathway and methods of use
AU2002361654A8 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
AU2003215004A8 (en) Msrebps as modifiers of the srebp pathway and methods of use
AU2003213662A8 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
AU2003295928A8 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
AU2003223208A8 (en) Mp21s as modifiers of the p21 pathway and methods of use
AU2002303947A1 (en) Pecis as modifiers of the p53 pathway and methods of use

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase